May 2nd 2024
The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.
Clinical Decision Support System May Aid Hypertension Management, Improve Clinical Outcomes in CKD
March 15th 2024Patients whose primary care practitioners were randomized to a clinical decision support system intervention achieved a statistically significant reduction in SBP versus usual care but had similar rates of BP control.
Semaglutide 1.0 mg (Ozempic) Reduced Kidney Events 24% in FLOW Trial
March 5th 2024Novo Nordisk announced topline data from the FLOW trial indicate semaglutide 1.0 mg (Ozempic) was associated with a 24% reduction in risk of kidney disease-related events among individuals with type 2 diabetes and CKD compared to placebo therapy.
Home-Based Albuminuria Screening Cost-Effective for Preventing Kidney, Cardiovascular Events
February 6th 2024Findings highlight the potential benefits of implementing home-based screening for albuminuria in the general population to reduce the burden of kidney and cardiovascular diseases while maintaining cost-effectiveness.
eGFR Based on Creatinine, Cystatin C May Offer Better CKD Threshold for Older Adults
January 31st 2024Low eGFRcr-cys was more strongly and uniformly associated with adverse outcomes compared to low eGFRcr in an older patient population, highlighting the benefit of including cystatin C in GFR estimation.
Automated AKI Alert Prompts Change of Care, Shows No Impact on Patient Outcomes
January 26th 2024Use of the electronic AKI alert system led to slight improvements in intervention rates and AKI diagnosis, although kidney function and patient-centered outcomes did not differ from patients receiving usual care.
CBT-I, Trazodone Ineffective at Improving Insomnia for Patients on Hemodialysis
January 18th 2024Investigators observed no change in Insomnia Severity Index scores from baseline to weeks 7 and 25 with CBT-1, trazodone, or placebo, suggesting these insomnia treatment options are not effective for patients undergoing hemodialysis.
SGLT-2is Mitigate Risk of Cardiovascular, Kidney Diseases in Patients with Type 2 Diabetes and AKD
January 4th 2024Compared to nonusers, patients with type 2 diabetes and acute kidney disease administered SGLT-2is had a significantly lower risk of mortality, major adverse kidney events, and major adverse cardiovascular events.